imatinib mesylate has been researched along with Adenocystic Carcinoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atahan, S; Atayoglu, AT; Demiray, H; Demiray, M; Sahinbas, H; Selcuk, D; Yildirim, I | 1 |
| Bruce, I; Ghosal, N; Hastings, D; Homer, J; Julyan, P; Mais, K; Ryder, WD; Shenjere, P; Slevin, NJ; Ward, T | 1 |
| Alcedo, JC; Arosemena, JR; Fábrega, JM; Urrutia, A | 1 |
| Brown, S; Chen, EX; Hotte, SJ; Lamont, E; MacKenzie, M; Murgo, A; Pond, GR; Siu, LL; Vokes, E; Winquist, EW | 1 |
| Bruce, IA; Homer, JJ; McGown, AT; Slevin, NJ; Ward, TH | 1 |
| Berthaud, P; Casiraghi, O; Faivre, S; Raymond, E; Temam, S | 1 |
| Hong, RL; Hsu, C; Jeng, YM; Lin, CH; Tzen, CY; Yen, RF | 1 |
| Catane, R; Levitt, M; Pfeffer, MR; Symon, Z; Talmi, Y; Yosepovitch, A | 1 |
4 trial(s) available for imatinib mesylate and Adenocystic Carcinoma
| Article | Year |
|---|---|
Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Adenoid Cystic; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Imatinib Mesylate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography, Thoracic; Radiopharmaceuticals; Remission Induction; Salivary Gland Neoplasms; Survival Rate; Tomography, X-Ray Computed; Young Adult | 2011 |
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Salivary Gland Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzamides; Carcinoma, Adenoid Cystic; Disease Progression; DNA Mutational Analysis; Female; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Piperazines; Pleural Effusion, Malignant; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Carcinoma, Adenoid Cystic; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Salivary Gland Neoplasms | 2007 |
4 other study(ies) available for imatinib mesylate and Adenocystic Carcinoma
| Article | Year |
|---|---|
Successful treatment of c-kit-positive metastatic Adenoid Cystic Carcinoma (ACC) with a combination of curcumin plus imatinib: A case report.
Topics: Antineoplastic Agents; Carcinoma, Adenoid Cystic; Curcumin; Drug Therapy, Combination; Humans; Imatinib Mesylate; Male; Middle Aged; Proto-Oncogene Proteins c-kit | 2016 |
Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Adenoid Cystic; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salivary Gland Neoplasms; Treatment Outcome | 2004 |
Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Adenoid Cystic; Carcinoma, Squamous Cell; Cell Line, Tumor; Comet Assay; Drug Antagonism; Drug Synergism; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Adenoid Cystic; DNA Mutational Analysis; Gene Expression Profiling; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Salivary Gland Neoplasms | 2005 |